Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)
Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) said its China VIE, Shuhai Jingwei, completed FDA establishment registration and device listing for the NeuroVibe acoustic biofeedback system (NV-02, NV-03). The devices were listed as Class II 510(k)-exempt biofeedback medical devices under FDA product code HCC. Datasea said this supports U.S. commercialization planning; listing is not FDA approval.
How this was made
The 30-second read
Why it matters
The company frames FDA establishment registration and device listing as moving NeuroVibe from R&D toward a regulated product platform for US commercialization, but the release explicitly disclaims FDA approval/clearance.
Market read
This is a concrete regulatory milestone for a specific device platform, but it is not FDA clearance, so traders may treat it as a de-risking step rather than a definitive commercialization green light.
What to watch
Traders should watch for evidence of reimbursement, clinical outcomes, manufacturing readiness, and whether any additional FDA steps are required beyond listing for the intended claims.
Background
Datasea is developing an acoustic AI and non-invasive BCI biofeedback system (NeuroVibe) and is using a China VIE structure for FDA-related activities.
Ticker impact
Datasea says its China VIE Shuhai Jingwei completed FDA establishment registration and listed NeuroVibe NV-02/NV-03 as Class II 510(k)-exempt biofeedback devices.
Near-term upside bias possible on commercialization optimism, with follow-through likely dependent on subsequent clinical/market validation and any later FDA clearance steps.
The article discloses a fresh FDA-related administrative milestone (establishment registration and product listing) and specific product codes (HCC) and device class (Class II 510(k)-exempt). However, it explicitly states this is not FDA approval/clearance, limiting immediate fundamental re-rating.
Market effects
Supports the broader non-invasive neurotechnology and biofeedback device commercialization narrative, but does not establish clinical efficacy or clearance.
US regulatory pathway progress for a China-based VIE may improve perceived access to the US medtech market.
Could strengthen Datasea’s positioning for global adoption claims, though the milestone is US-focused and administrative rather than approval-based.
Counterpoint
Because the release stresses no FDA approval/clearance, the market may already price in “paper” regulatory progress, limiting sustained impact.
Key entities
- companyDatasea Intelligent Technology Ltd.
NASDAQ-listed company announcing FDA establishment registration and device listing for its NeuroVibe biofeedback system via its China VIE.
- VIEShuhai Jingwei (Shenzhen) Information Technology Co., Ltd.
Datasea’s variable interest entity in China that completed FDA establishment registration and device listing for NeuroVibe products NV-02 and NV-03.
- medical deviceNeuroVibe Biofeedback System (NV-02, NV-03)
Non-invasive biofeedback system listed under FDA product code HCC as Class II 510(k)-exempt devices.
- regulatory classificationFDA product code HCC
The FDA product code under which NeuroVibe NV-02 and NV-03 are listed as Class II 510(k)-exempt biofeedback devices.
